Systematic Review

Accepted on 22 Mar 2024

Systematic review of drug-drug interactions of delta-9tetrahydrocannabinol, cannabidiol, and Cannabis

in Pharmacogenetics and Pharmacogenomics

Rahul Nachnani
Amy Knehans
Jeffrey Neighbors
Paul T Kocis
Tzuo Lee
Kayla Tegeler
Thomas Trite
Wesley M Raup-Konsavage
Kent E Vrana

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1282831

146 views

Original Research

Published on 22 Mar 2024

Effect of NAT2, GSTM1 and CYP2E1 genetic polymorphisms on plasma concentration of isoniazid and its metabolites in patients with tuberculosis, and the assessment of exposure-response relationships

in Pharmacogenetics and Pharmacogenomics

Viktorija Ulanova
Agnija Kivrane
Anda Viksna
Leonora Pahirko
Lauma Freimane
Darja Sadovska
Iveta Ozere
Andra Cirule
Eduards Sevostjanovs
Solveiga Grinberga

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1332752

861 views
1 citation

Review

Published on 13 Mar 2024

Landscape of m6A RNA methylation regulators in liver cancer and its therapeutic implications

in Pharmacogenetics and Pharmacogenomics

Jindu Zhao
Guo-Ying Li
Xian-Ying Lu
Li-Ran Zhu
Qun Gao

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1376005

834 views

Original Research

Published on 11 Mar 2024

Development and validation of a pharmacogenomics reporting workflow based on the illumina global screening array chip

in Pharmacogenetics and Pharmacogenomics

Pamela Gan
Muhammad Irfan Bin Hajis
Mazaya Yumna
Jessline Haruman
Husnul Khotimah Matoha
Dian Tri Wahyudi
Santha Silalahi
Dwi Rizky Oktariani
Fitria Dela
Tazkia Annisa

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1349203

1,153 views

Original Research

Published on 08 Mar 2024

Prediction of antipsychotics efficacy based on a polygenic risk score: a real-world cohort study

in Pharmacogenetics and Pharmacogenomics

Marco De Pieri
Marco Ferrari
Giorgio Pistis
Franziska Gamma
Franca Marino
Armin Von Gunten
Philippe Conus
Marco Cosentino
Chin-Bin Eap

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1274442

924 views

Original Research

Published on 28 Feb 2024

Effect of high NEFA concentration on lipid metabolism disorders in hepatocytes based on lipidomics

in Pharmacogenetics and Pharmacogenomics

Xinyi Fan
Jie Xu
Yuan Hu
Kui Wang
Yiyi Zhao
Jinyin Cai
Xinyuan Zhang
Binghai Pan
Anqi Xu
Yajing Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1372296

986 views
1 citation

Correction

Published on 27 Feb 2024

Corrigendum: Precision medicine: a new era for inner ear diseases

in Pharmacogenetics and Pharmacogenomics

Elisa Tavazzani
Paolo Spaiardi
Donatella Contini
Giulio Sancini
Giancarlo Russo
Sergio Masetto

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1385698

482 views

Original Research

Published on 26 Feb 2024

NeuroPredict: study of the predictive value of ABCB1 genetic polymorphisms and associated clinical factors in chronic chemotherapy-induced peripheral neuropathy (CIPN)

in Pharmacogenetics and Pharmacogenomics

Alicia Vargas-Aliaga
María De la Haba
María José Contreras
Cristina Morales Estevez
Ignacio Porras
María Teresa Cano
Gema Pulido
María Auxiliadora Gómez
Pablo Flores-Paco
De La Haba-Rodriguez Juan

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1352939

968 views

Original Research

Published on 19 Feb 2024

Influence of cytochrome P450 2D610/10 genotype on the risk for tramadol associated adverse effects: a retrospective cohort study

in Pharmacogenetics and Pharmacogenomics

Mahmood Mahajna
Rami Abu Fanne
Mahmoud Odeh
Matitiahu Berkovitch
Elias Tannous
Sara Eyal
Shlomo Vinker
Ilan Green
Ilan Matok

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1358549

851 views

Review

Published on 14 Feb 2024

From genes to drugs: CYP2C19 and pharmacogenetics in clinical practice

in Pharmacogenetics and Pharmacogenomics

Qamar Shubbar
Aminah Alchakee
Khaled Walid Issa
Abdul Jabbar Adi
Ali Ibrahim Shorbagi
Maha Saber-Ayad

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1326776

1,771 views

Original Research

Published on 08 Feb 2024

Assessment of the current status of real-world pharmacogenomic testing: informed consent, patient education, and related practices

in Pharmacogenetics and Pharmacogenomics

Lucas Pereira
Cyrine-Eliana Haidar
Susanne B. Haga
Anna G. Cisler
April Hall
Sanjay K. Shukla
Scott J. Hebbring
Emili J. W. Leary

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1355412

1,415 views

Brief Research Report

Published on 06 Feb 2024

NUDT15 and TPMT polymorphisms in three distinct native populations of the Brazilian Amazon

in Pharmacogenetics and Pharmacogenomics

Jamila Alessandra Perini
Paulo Cesar Basta
Guilherme Suarez-Kurtz

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1359570

648 views

Original Research

Published on 05 Feb 2024

Neurodegeneration: can metabolites from Eremurus persicus help?

in Pharmacogenetics and Pharmacogenomics

Valeria Cavalloro
Nicoletta Marchesi
Pasquale Linciano
Daniela Rossi
Lucrezia Irene Maria Campagnoli
Alice Fossati
Karzan Mahmood Ahmed
Alessio Malacrida
Mariarosaria Miloso
Giuseppe Mazzeo

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1309766

1,510 views

Review

Published on 05 Feb 2024

Pharmacogenomics and non-genetic factors affecting drug response in autism spectrum disorder in Thai and other populations: current evidence and future implications

in Pharmacogenetics and Pharmacogenomics

Mohitosh Biswas
Natchaya Vanwong
Chonlaphat Sukasem

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1285967

1,550 views

Original Research

Published on 05 Feb 2024

Exploratory focused pharmacogenetic testing reveals novel markers associated with risperidone pharmacokinetics in Saudi children with autism

in Pharmacogenetics and Pharmacogenomics

Sireen Abdul Rahim Shilbayeh
Iman Sharaf Adeen
Ezzeldeen Hasan Ghanem
Haya Aljurayb
Khawlah Essa Aldilaijan
Fatimah AlDosari
Abeer Fadda

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1356763

1,032 views

Original Research

Published on 02 Feb 2024

Measurement of CYP1A2 and CYP3A4 activity by a simplified Geneva cocktail approach in a cohort of free-living individuals: a pilot study

in Pharmacogenetics and Pharmacogenomics

Constance A. Sobsey
Noor Mady
Vincent R. Richard
Andre LeBlanc
Thomas Zakharov
Christoph H. Borchers
R. Thomas Jagoe

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1232595

1,491 views

Navigation group

Articles

Systematic review of drug-drug interactions of delta-9tetrahydrocannabinol, cannabidiol, and Cannabis

Effect of NAT2, GSTM1 and CYP2E1 genetic polymorphisms on plasma concentration of isoniazid and its metabolites in patients with tuberculosis, and the assessment of exposure-response relationships

Landscape of m6A RNA methylation regulators in liver cancer and its therapeutic implications

Development and validation of a pharmacogenomics reporting workflow based on the illumina global screening array chip

Prediction of antipsychotics efficacy based on a polygenic risk score: a real-world cohort study

Effect of high NEFA concentration on lipid metabolism disorders in hepatocytes based on lipidomics

Corrigendum: Precision medicine: a new era for inner ear diseases

NeuroPredict: study of the predictive value of ABCB1 genetic polymorphisms and associated clinical factors in chronic chemotherapy-induced peripheral neuropathy (CIPN)

Influence of cytochrome P450 2D610/10 genotype on the risk for tramadol associated adverse effects: a retrospective cohort study

From genes to drugs: CYP2C19 and pharmacogenetics in clinical practice

Assessment of the current status of real-world pharmacogenomic testing: informed consent, patient education, and related practices

NUDT15 and TPMT polymorphisms in three distinct native populations of the Brazilian Amazon

Neurodegeneration: can metabolites from Eremurus persicus help?

Pharmacogenomics and non-genetic factors affecting drug response in autism spectrum disorder in Thai and other populations: current evidence and future implications

Exploratory focused pharmacogenetic testing reveals novel markers associated with risperidone pharmacokinetics in Saudi children with autism

Measurement of CYP1A2 and CYP3A4 activity by a simplified Geneva cocktail approach in a cohort of free-living individuals: a pilot study

Navigation group

Articles

Systematic review of drug-drug interactions of delta-9tetrahydrocannabinol, cannabidiol, and Cannabis

Effect of NAT2, GSTM1 and CYP2E1 genetic polymorphisms on plasma concentration of isoniazid and its metabolites in patients with tuberculosis, and the assessment of exposure-response relationships

Landscape of m6A RNA methylation regulators in liver cancer and its therapeutic implications

Development and validation of a pharmacogenomics reporting workflow based on the illumina global screening array chip

Prediction of antipsychotics efficacy based on a polygenic risk score: a real-world cohort study

Effect of high NEFA concentration on lipid metabolism disorders in hepatocytes based on lipidomics

Corrigendum: Precision medicine: a new era for inner ear diseases

NeuroPredict: study of the predictive value of ABCB1 genetic polymorphisms and associated clinical factors in chronic chemotherapy-induced peripheral neuropathy (CIPN)

Influence of cytochrome P450 2D6*10/*10 genotype on the risk for tramadol associated adverse effects: a retrospective cohort study

From genes to drugs: CYP2C19 and pharmacogenetics in clinical practice

Assessment of the current status of real-world pharmacogenomic testing: informed consent, patient education, and related practices

NUDT15 and TPMT polymorphisms in three distinct native populations of the Brazilian Amazon

Neurodegeneration: can metabolites from Eremurus persicus help?

Pharmacogenomics and non-genetic factors affecting drug response in autism spectrum disorder in Thai and other populations: current evidence and future implications

Exploratory focused pharmacogenetic testing reveals novel markers associated with risperidone pharmacokinetics in Saudi children with autism

Measurement of CYP1A2 and CYP3A4 activity by a simplified Geneva cocktail approach in a cohort of free-living individuals: a pilot study

Influence of cytochrome P450 2D610/10 genotype on the risk for tramadol associated adverse effects: a retrospective cohort study